Listed

PharmaCyte Biotech, Inc.: Form 10-Q for the period ended Jan 31, 2021

Filed with the SEC on Mar 12, 2021 and accepted by EDGAR at Mar 12, 2021, 17:11 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-01-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2020-11-01 to 2021-01-31$0us-gaap:Revenues
Revenue9 months2020-05-01 to 2021-01-31$0us-gaap:Revenues
Research and development3 months2020-11-01 to 2021-01-31$174.1kus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2020-05-01 to 2021-01-31$596.0kus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2020-11-01 to 2021-01-31−$756.8kus-gaap:OperatingIncomeLoss
Operating income9 months2020-05-01 to 2021-01-31−$2.6mus-gaap:OperatingIncomeLoss
Interest expense3 months2020-11-01 to 2021-01-31$249us-gaap:InterestExpense
Interest expense9 months2020-05-01 to 2021-01-31$2.0kus-gaap:InterestExpense
Net income3 months2020-11-01 to 2021-01-31−$757.1kus-gaap:NetIncomeLoss
Net income9 months2020-05-01 to 2021-01-31−$2.6mus-gaap:NetIncomeLoss
Diluted EPS3 months2020-11-01 to 2021-01-31$0.00us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS9 months2020-05-01 to 2021-01-31$0.00us-gaap:EarningsPerShareBasicAndDiluted
Diluted shares (weighted)3 months2020-11-01 to 2021-01-312,337,034,318 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2020-05-01 to 2021-01-312,108,274,833 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2020-05-01 to 2021-01-31−$2.4mus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2021-01-31$3.1mus-gaap:Cash
Current assetsAt period end2021-01-31$3.1mus-gaap:AssetsCurrent
Total assetsAt period end2021-01-31$8.3mus-gaap:Assets
Current liabilitiesAt period end2021-01-31$640.3kus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2021-01-31$648.7kus-gaap:Liabilities
Shareholders' equityAt period end2021-01-31$7.6mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001683168-21-000925. Last ingested by Listed: Nov 14, 2026, 20:52 ET. Listed shows no prices and gives no investment advice.